Key result
Selective serotonin reuptake inhibitors (SSRIs) require careful safety considerations regarding their use and selection in patients with major depressive disorder and comorbid cardiovascular disease.
Why the study?
Major depressive disorder increases morbidity and mortality in CVD, and while SSRIs are commonly used cornerstones of treatment, clinicians must weigh safety considerations before prescribing them.
Which SSRI is safest for patients with cardiovascular disease and major depressive disorder?
Which SSRI is safest for patients with cardiovascular disease and major depressive disorder?
This review discusses the safety considerations and selection of SSRIs for patients with comorbid cardiovascular disease and major depressive disorder.
Major depressive disorder is a common mood disorder and presents increased morbidity and mortality risks for patients with comorbid cardiovascular disease (CVD). Selective serotonin reuptake inhibitors (SSRIs) are a cornerstone of treatment for major depressive disorder, given their relative safety and affordability compared with other antidepressant classes, and SSRIs frequently are used in patients with CVD. However, clinicians should carefully weigh safety considerations before prescribing SSRIs in these patients. This article reviews the safety of SSRIs in patients with CVD and discusses SSRI selection.
No takes yet. Share an insight, caveat, or question.
Dunham et al. (2021) conducted a review in Major depressive disorder and cardiovascular disease. Selective serotonin reuptake inhibitors (SSRIs) was evaluated. Selective serotonin reuptake inhibitors (SSRIs) require careful safety considerations regarding their use and selection in patients with major depressive disorder and comorbid cardiovascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: